131 HARTWELL AVENUE, LEXINGTON, MA
Investor Presentation
Annual Report to Security Holders
Director Departure - Martin J. Joyce Not Standing for Re-Election
Other Events
Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
Chief Development Officer Resignation - Stephen G. Machatha Steps Down
Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
Q1
FY 2024
Q3
Q2
Amended Annual Report
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
S-8 POS
Confidential Treatment Order